VA
IPSC icon

Verdad Advisers’s Century Therapeutics IPSC Stock Holding History

Verdad Advisers’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113K Buy
+46,200
New +$106K 0.11% 184

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Verdad Advisers's IPSC Position: Q2 2026 in Review

Verdad Advisers opened a new position in Century Therapeutics (IPSC) in Q2 2026: 46,200 shares worth $113K. The stake represents 0.11% of the portfolio and ranks #184 among its holdings.

99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Verdad Advisers held 46,200 shares of Century Therapeutics worth $113K as of Q2 2026.
  • Century Therapeutics was a new Verdad Advisers position in Q2 2026.
  • Century Therapeutics made up 0.11% of Verdad Advisers's portfolio in Q2 2026, its #184 holding.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.